Video: Partnership Unites UCB with Consumer Product Innova...( -- UCB offers Cimzia(R) (certolizuma...),Health

-- UCB offers Cimzia(R) (certolizumab pegol), a treatment option for adults with moderately to severely active rheumatoid arthritis and moderate to severe Crohn's disease, to U.S. patients in an exclusively designed prefilled syringe resulting from the UCB partnership with OXO(R)

-- Rheumatoid arthritis patients directly involved with UCB and OXO(R) in the development of the new Cimzia(R) prefilled syringe

-- Cimzia(R) prefilled syringe designed to make self-administration easy for people living with rheumatoid arthritis

ATLANTA, May 14 /PRNewswire/ -- In a long-term partnership agreement, UCB, a global biopharmaceutical leader, has teamed up with OXO(R), a celebrated consumer products company, to offer patients a syringe and packaging components that take into account some of the challenges many rheumatoid arthritis (RA) patients face when self-administrating their medicine. UCB's Cimzia(R) (certolizumab pegol) was approved this week by the U.S. Food and Drug Administration (FDA) and offers a treatment option for adults with moderately to severely active rheumatoid arthritis. Cimzia(R) is also approved for reducing signs and symptoms of Crohn's disease and maintaining clinical response in adult patients with moderate to severely active disease who have had an inadequate response to conventional therapy. The new prefilled syringe is now also available to U.S. Crohn's patients taking Cimzia(R) for subcutaneous self-administration. The new syringe carries the Arthritis Foundation's Ease-of-Use Commendation, signifying a positive review of the syringe design by the Arthritis Foundation's(TM) independent research laboratory.

To view the Multimedia News Release, go to: http://www.prnewswire.com/mnr/cimzia/35009/

The companies recognized the importance of designing a syringe and pac
'/>"/>